Antibiotic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibiotic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of antibiotic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter antibiotic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 126 antibiotic deals announced since 2016 including financial terms where available including links to online deal records of actual antibiotic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of antibiotic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in antibiotic dealmaking since 2016.
Chapter 3 provides an overview of the leading antibiotic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotic dealmaking with a brief summary followed by a comprehensive listing of antibiotic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of antibiotic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of antibiotic partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibiotic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in antibiotic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• Browse antibiotic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
• Directory of antibiotic deal records covering pharmaceutical and biotechnology
• The leading antibiotic deals by value
• Most active antibiotic licensing dealmakers
Antibiotic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Fully revised and updated, the report provides details of antibiotic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter antibiotic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 126 antibiotic deals announced since 2016 including financial terms where available including links to online deal records of actual antibiotic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of antibiotic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in antibiotic dealmaking since 2016.
Chapter 3 provides an overview of the leading antibiotic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotic dealmaking with a brief summary followed by a comprehensive listing of antibiotic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of antibiotic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of antibiotic partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibiotic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in antibiotic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Antibiotic Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016• Browse antibiotic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Antibiotic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibiotic trends and structure of deals entered into by leading biopharma companies worldwide.Antibiotic Collaboration and Licensing Deals includes:
• Trends in antibiotic dealmaking in the biopharma industry• Directory of antibiotic deal records covering pharmaceutical and biotechnology
• The leading antibiotic deals by value
• Most active antibiotic licensing dealmakers
Antibiotic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Antibiotic dealmaking by technology type
Chapter 2 - Trends in antibiotic dealmaking
Chapter 3 - Leading antibiotic deals
Chapter 4 - Most active antibiotic dealmakers
Chapter 5 - Antibiotic contracts dealmaking directory
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Oxford Drug Design
- Gilead Sciences
- MD Anderson Cancer Center
- Biomedical Advanced Research and Development Authority
- Lysando
- Warp Drive Bio
- Centre for Drug Research and Development (CDRD)
- InSite Vision
- France's General Directorate for Armaments
- Q-linea AB
- Basilea Pharmaceutica
- European Commission
- European Union
- XBiotech
- QureTech Bio
- AnnaMed
- Dr. Reddy's Laboratories
- NovaMedica
- The Medicines Company
- The Regents of the University of California
- Paratek Pharmaceuticals
- Stiefel Laboratories
- Decibel Therapeutics
- NacuGen Therapeutics
- Quotient Bioresearch
- Emergent BioSolutions
- Novasep
- Polypeptide Laboratory
- Premier Inc
- Optimer Pharmaceuticals
- Auspherix
- Strides Arcolab
- Synthetic Biologics
- Medimetriks
- SINTEF
- Dana-Farber Cancer Institute
- Finorga
- Allergan
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
